<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="9434">Telmisartan</z:chebi> is an <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor blocker and partial peroxisome proliferator-activated receptor gamma <z:chebi fb="4" ids="48705">agonist</z:chebi> that modulates the renin-angiotensin-<z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> system </plain></SENT>
<SENT sid="1" pm="."><plain>It is used primarily to manage <z:hpo ids='HP_0000822'>hypertension</z:hpo>, diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, and <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Recent studies have reported that <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (MI) has occurred in <z:chebi fb="0" ids="9434">telmisartan</z:chebi>-treated patients </plain></SENT>
<SENT sid="3" pm="."><plain>The purpose of the study was to investigate the specific conditions and underlying mechanisms that may result in <z:chebi fb="0" ids="9434">telmisartan</z:chebi>-induced MI </plain></SENT>
<SENT sid="4" pm="."><plain>We evaluated the effect of <z:chebi fb="0" ids="9434">telmisartan</z:chebi> on whole hearts, cardiomyocytes, and cardiac sarcolemmal ion channels </plain></SENT>
<SENT sid="5" pm="."><plain>Hearts of 8-week-old male Sprague-Dawley rats were perfused with 3, 10, 30, or 100 μM <z:chebi fb="0" ids="9434">telmisartan</z:chebi> or <z:chebi fb="0" ids="6541">losartan</z:chebi> or with <z:mpath ids='MPATH_458'>normal</z:mpath> Tyrode's solution (control) for 3 h </plain></SENT>
<SENT sid="6" pm="."><plain>We found that <z:chebi fb="0" ids="9434">telmisartan</z:chebi> induced <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, with an <z:mpath ids='MPATH_124'>infarct</z:mpath> size of 21 % of the total at 30 μM (P &lt; 0.0001) and 63 % of the total area at 100 μM (P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="9434">Telmisartan</z:chebi> also induced cardiac dysfunction (e.g., <z:mp ids='MP_0005333'>decreased heart rate</z:mp>, diminished coronary flow, hypercontracture, and <z:hpo ids='HP_0011675'>arrhythmia</z:hpo>) </plain></SENT>
<SENT sid="8" pm="."><plain>Confocal microscopy demonstrated that 30 μM <z:chebi fb="0" ids="9434">telmisartan</z:chebi> significantly elevated the intracellular Ca(2+) level, leading to hypercontracture and cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Patch clamp analysis of isolated cardiomyocytes revealed that <z:chebi fb="0" ids="9434">telmisartan</z:chebi> induced <z:chebi fb="0" ids="29101">Na(+)</z:chebi> overload by slowing the inactivation of voltage-gated <z:chebi fb="0" ids="29101">Na(+)</z:chebi> current (I (Na)), activating the reverse mode of <z:chebi fb="0" ids="29101">Na(+)</z:chebi>-Ca(2+) exchanger activity, and causing Ca(2+) overload </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="9434">Telmisartan</z:chebi> significantly delayed the inactivation of the voltage-gated <z:chebi fb="0" ids="29101">Na(+)</z:chebi> channel, causing cytosolic <z:chebi fb="0" ids="29101">Na(+)</z:chebi> overload, prolonged action potential duration, and subsequent Ca(2+) overload </plain></SENT>
<SENT sid="11" pm="."><plain>Above 30 μM, <z:chebi fb="0" ids="9434">telmisartan</z:chebi> may potentially cause cardiac cell <z:hpo ids='HP_0011420'>death</z:hpo> and MI </plain></SENT>
</text></document>